The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 45 results
Sort by date: Descending
Encores: Not included
SLEEP (Annual Meeting of the Associated Professional Sleep Societies)
June 7th – 11th 2025
Sleep-wake disorders
PRESENTATION
Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients with Narcolepsy and Idiopathic Hypersomnia
AUTHOR(S)

Presented by Julia Chapman

View presentation
Sleep-wake disorders
Sleep-wake disorders
POSTER
Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients With Narcolepsy and Idiopathic Hypersomnia
AUTHOR(S)

Meera Modi,1 Brendon Yee,2 Julia Chapman,2 Angela D’Rozario,2 Roman Rosipal,3 Leonardo Jose Trejo,3 G.S.F. Ruigt,3 Ron Grunstein,2 Bhaskar Rege,1 Daniel G. Smith1

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Evaluation of the Novel Orexin 2 Receptor Agonist ALKS 2680 on Measures of Arousal Circuit Activation in Rodents
AUTHOR(S)

Julie M. Brooks,1 Angelica M. Patino,1 Corey B. Puryear,1 Laura A. Tan,1 Brian Raymer1

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
American Society of Clinical Psychopharmacology
May 27th – 30th 2025
Bipolar Disorder
Schizophrenia
POSTER
Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Alexandra Lovett, MD,2 Christoph U. Correll, MD3-6

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
International Society for Pharmacoeconomics and Outcomes Research, Inc
May 13th – 16th 2025
Sleep-wake disorders
POSTER
The Economic Burden of Narcolepsy in the United States: Matched Analysis of National Health and Wellness Survey Data
AUTHOR(S)

Michael J. Doane1, Kiran P. Maski2, M. Janelle Cambron-Mellott3, Shakiba Eslamimehr3, Adam Jauregui3, Wilbur P. Williams, III1

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Academy of Managed Care Pharmacy
March 31st – April 3rd 2025
Schizophrenia
POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane,1 Regina Grebla,2 Michael J. Doane,2 Andrea B. Barthel,3 Chenxue Liang,3 Zhengfan Wang,3 Elizabeth S. Nagelhout,3 Lauren N. Strand2

View poster
Listen to Audio Abstract
0:00 0:00
Schizophrenia